PassPort Technologies, Inc.
Wednesday, June 05, 2024
Company Presentation
![Platform for Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 4
PassPort Technologies is a clinical stage drug and medical device development company with its proprietary groundbreaking transdermal microporation platform, PassPort® System. The PassPort® System allows for painless and needle-free delivery of peptides/proteins, antigen/mRNA vaccines, and small molecules via skin. The leading project in our pipelines is Zolmitriptan PassPort®, Best-in-Class, for the treatment of acute migraine with interim positive results in Phase 1 clinical studies. The 2nd clinical candidate, ALC PassPort®, First-in-Class novel peptide drug, is for the treatment of Alzheimer's Disease. PassPort Technologies was founded in 2019 in San Diego, CA and is owned by Axcelead, Inc.
![PassPort Technologies, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1770444-1-JPG(1).png)
Company Website:
https://passport-tech.com/
Lead Product in Development:
Zolmitriptan PassPort® & ALC PassPort®
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Five (5) and platform technologies
Company HQ City
San Diego
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Tomoyuki Fujisawa (President & CEO)
Development Phase of Primary Product
Phase I
Primary Speaker